Company intelligence / Profile preview

Beta Bionics

Irvine, California, United Statesbetabionics.com ↗

Ownership: Public · BBNX
Employees: ~291
Development stage: Commercial

Overview

Beta Bionics has commercialized the iLet Bionic Pancreas for people aged six and up with type 1 diabetes. The system was FDA-cleared in May 2023. Since launch, quarterly revenues have grown from $3.1M to $16.7M as of late 2024/early 2025. The company plans further studies and regulatory submissions to expand use into type 2 diabetes.

Therapeutic areas: Endocrinology
Modalities: DeviceBiologicSmall molecule
Industry: Physiological Monitoring

Partnerships

DexcomAbbott

Financials

Market cap: $869.7M
Total revenue: $32M
Enterprise value: $695.7M

Beyond the preview

Go deeper on Beta Bionics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta Bionics.

Explore the full profile